Education
About Us
Working with TipRanks
Follow Us
Spineway SA (FR:ALSPW)
:ALSPW
Top Page
Spineway SA
(ALSPW)
Select Model
Select Model
Rating:50Neutral
Price Target:
€0.00
▼(-100.00% Downside)
Spineway SA's overall stock score is driven by strong revenue growth and positive technical indicators, but is significantly hampered by ongoing profitability challenges and negative valuation metrics. The stable balance sheet provides some support, but liquidity concerns remain a risk.
Spineway SA (ALSPW) vs. iShares MSCI France ETF (EWQ)
Market Cap
€5.47M
Dividend YieldN/A
Average Volume (3M)1.29M
Price to Earnings (P/E)―
Beta (1Y)6.64
Revenue Growth-5.46%
EPS Growth99.75%
CountryFR
Employees48
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.12
Shares Outstanding35,544,390
10 Day Avg. Volume3,343,126
30 Day Avg. Volume1,288,542
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00485
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Spineway SA Business Overview & Revenue Model
Company DescriptionSpineway SA (ALSPW) is a French company specializing in the design, manufacture, and marketing of innovative spinal implants and surgical instruments. Operating primarily in the medical device sector, Spineway focuses on providing solutions for spinal surgery, including products for degenerative and traumatic pathologies. The company aims to enhance surgical outcomes through its advanced technology and dedicated service to healthcare professionals.
How the Company Makes MoneySpineway generates revenue primarily through the sale of its spinal implant products and surgical instruments to hospitals and medical facilities. The company’s revenue model is based on direct sales, as well as potential partnerships with distributors and medical institutions. Key revenue streams include the sale of various spinal implants, such as intervertebral cages, screws, and rods, as well as surgical instruments used in spinal procedures. Additionally, Spineway may benefit from ongoing relationships with healthcare providers, offering training and support services that can lead to repeat business and long-term contracts.
Spineway SA Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.15M | 10.52M | 7.43M | 4.29M | 3.38M | 5.59M |
| Gross Profit | 6.07M | 1.63M | 237.00K | -1.45M | -2.12M | 1.90M |
| EBITDA | 2.24M | -4.79M | -2.76M | -719.00K | -1.32M | -1.55M |
| Net Income | -1.89M | -6.51M | -3.14M | -1.58M | -14.05M | -2.88M |
Balance Sheet | ||||||
| Total Assets | 30.20M | 26.31M | 27.70M | 25.57M | 14.75M | 12.77M |
| Cash, Cash Equivalents and Short-Term Investments | 4.03M | 1.80M | 5.50M | 13.89M | 4.86M | 2.58M |
| Total Debt | 1.55M | 2.60M | 2.92M | 2.40M | 2.89M | 4.61M |
| Total Liabilities | 6.34M | 7.26M | 5.69M | 4.69M | 4.73M | 6.28M |
| Stockholders Equity | 23.86M | 19.05M | 22.00M | 20.88M | 10.02M | 6.49M |
Cash Flow | ||||||
| Free Cash Flow | 580.00K | -7.29M | -13.89M | -2.88M | -1.39M | -6.37M |
| Operating Cash Flow | 580.00K | -5.83M | -1.62M | -1.79M | -408.00K | -1.16M |
| Investing Cash Flow | -1.41M | -1.39M | -10.20M | -578.00K | -979.00K | -5.21M |
| Financing Cash Flow | 3.23M | 3.49M | 3.72M | 11.45M | 3.67M | 8.96M |
Spineway SA Technical Analysis
Neutral
0.15
Price Trends
0.14
Positive
0.13
Positive
0.12
Positive
Market Momentum
<0.01
Positive
47.97
Neutral
33.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSPW, the sentiment is Neutral. The current price of 0.15 is below the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.14, and above the 200-day MA of 0.12, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.97 is Neutral, neither overbought nor oversold. The STOCH value of 33.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALSPW.
Spineway SA Peers Comparison
UnderperformOutperform
Sector (51)
FR:ALSPW
Spineway SA
0.15
<0.01
2.78%
GB:0RAF
Amplitude Surgical
6.20
2.98
92.55%
GB:0RAA
Safe Orthopaedics
188,520.00
0.00
0.00%
TCLIF
Theraclion SA
0.32
0.00
0.00%
DE:82F
NFL Biosciences SA
1.07
-0.93
-46.50%
DE:IM11
Implanet SA
0.27
0.16
145.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.